A phase II open-label randomized study to assess the efficacy and safety of selumetinib (AZD6244 [ARRY-142886]) versus capecitabine in patients with advanced or metastatic pancreatic cancer who have failed first-line gemcitabine therapy

✍ Scribed by György Bodoky, Constanta Timcheva, David Robert Spigel, Phillip Joseph La Stella, Tudor Eliade Ciuleanu, G. Pover, N. C. Tebbutt

• Book ID: 113064536
• Publisher: Springer US
• Year: 2011
• Tongue: English
• Weight: 640 KB
• Volume: 30
• Category: Article
• ISSN: 0167-6997
• DOI: 10.1007/s10637-011-9687-4